FR2936256B1 - Modulateurs de lgr5 dans le traitement de l'alopecie - Google Patents

Modulateurs de lgr5 dans le traitement de l'alopecie

Info

Publication number
FR2936256B1
FR2936256B1 FR0856316A FR0856316A FR2936256B1 FR 2936256 B1 FR2936256 B1 FR 2936256B1 FR 0856316 A FR0856316 A FR 0856316A FR 0856316 A FR0856316 A FR 0856316A FR 2936256 B1 FR2936256 B1 FR 2936256B1
Authority
FR
France
Prior art keywords
alopecia
modulators
lgr5
treatment
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0856316A
Other languages
English (en)
Other versions
FR2936256A1 (fr
Inventor
Sandrine Rethore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0856316A priority Critical patent/FR2936256B1/fr
Priority to CA2738002A priority patent/CA2738002A1/fr
Priority to EP09747891A priority patent/EP2331705A1/fr
Priority to PCT/FR2009/051771 priority patent/WO2010031980A1/fr
Priority to US13/120,104 priority patent/US20110236893A1/en
Publication of FR2936256A1 publication Critical patent/FR2936256A1/fr
Application granted granted Critical
Publication of FR2936256B1 publication Critical patent/FR2936256B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0856316A 2008-09-19 2008-09-19 Modulateurs de lgr5 dans le traitement de l'alopecie Expired - Fee Related FR2936256B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0856316A FR2936256B1 (fr) 2008-09-19 2008-09-19 Modulateurs de lgr5 dans le traitement de l'alopecie
CA2738002A CA2738002A1 (fr) 2008-09-19 2009-09-21 Modulateurs de lgr5 dans le traitement de l'alopecie
EP09747891A EP2331705A1 (fr) 2008-09-19 2009-09-21 Modulateurs de lgr5 dans le traitement de l'alopecie
PCT/FR2009/051771 WO2010031980A1 (fr) 2008-09-19 2009-09-21 Modulateurs de lgr5 dans le traitement de l'alopecie
US13/120,104 US20110236893A1 (en) 2008-09-19 2009-09-21 Lgr5 modulators in the treatment of alopecia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0856316A FR2936256B1 (fr) 2008-09-19 2008-09-19 Modulateurs de lgr5 dans le traitement de l'alopecie

Publications (2)

Publication Number Publication Date
FR2936256A1 FR2936256A1 (fr) 2010-03-26
FR2936256B1 true FR2936256B1 (fr) 2010-09-10

Family

ID=40566534

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0856316A Expired - Fee Related FR2936256B1 (fr) 2008-09-19 2008-09-19 Modulateurs de lgr5 dans le traitement de l'alopecie

Country Status (5)

Country Link
US (1) US20110236893A1 (fr)
EP (1) EP2331705A1 (fr)
CA (1) CA2738002A1 (fr)
FR (1) FR2936256B1 (fr)
WO (1) WO2010031980A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3143040A1 (fr) * 2022-12-12 2024-06-14 L'oreal Méthode de pronostic et/ou de diagnostic d’une perte de densité capillaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026248A1 (en) * 1998-03-26 2005-02-03 Hsueh Aaron J.W. Novel mammalian G-protein coupled receptors having extracellular leucine rich repeat regions
WO2005121374A2 (fr) * 2004-06-07 2005-12-22 Oklahoma Medical Research Foundation Analyse moleculaire de follicules pileux pour des maladies

Also Published As

Publication number Publication date
EP2331705A1 (fr) 2011-06-15
US20110236893A1 (en) 2011-09-29
CA2738002A1 (fr) 2010-03-25
FR2936256A1 (fr) 2010-03-26
WO2010031980A1 (fr) 2010-03-25

Similar Documents

Publication Publication Date Title
FR2936255B1 (fr) Modulateurs de fzd2 dans le traitement de l'alopecie
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
EA201190042A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
EA200971084A1 (ru) 5-членные гетероциклические амиды и родственные соединения
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
NO20073183L (no) Tetrahydrokinolinanalgoer som muskariniske agonister
EA200970931A1 (ru) Аналоги гетероариламидов
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA200900330A1 (ru) Аналоги 2-феноксипиримидинона
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
BRPI0922650A2 (pt) Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
DE60336452D1 (de) Fgfr agoniste
NZ706420A (en) Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
WO2007059064A3 (fr) Methodes associees au fgf2 pour diagnostiquer et traiter une depression
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
EP3839068A3 (fr) Procédés pour traiter, diagnostiquer, et surveiller le lupus
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
ATE456053T1 (de) Na+, k+-atpase-expression bei zervixdysplasie und krebs
ATE433115T1 (de) Timp-2 als ziel/marker des versagens von beta- zellen

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130531